The FDA is interested in the ability to scale and deploy a given therapy for a significant number of patients in the population, which can pose challenges when it comes to administering compounds like psychedelic drugs that require a substantial amount of time with a therapist. Additionally, there is confusion surrounding how to implement geroscience interventions, which focus on tying together the biology of aging with age-related diseases.